Delivering the Next Wave of Gene Therapies to the CNS

With systemic toxicity challenges plaguing the AAV field, direct administration for CNS indications creates an ideal target for gene therapy. This is an exciting year for the neurological space with clinical data to show and new biotechs coming out of the woodwork to release the next wave of gene therapies with more advanced CNS targeting for a wider selection of neurological targets.

The 4th Annual Gene Therapy for Neurological Disorders Summit will unite gene therapy developers with an industry-focused agenda across 4 days and 2 dedicated tracks of content to solve the preclinical, translational and clinical challenges of targeting a wide range of neurodevelopmental and neurodegenerative disorders with both ‘first’ and ‘next’ generation gene therapies.

Join the expanding audience of gene therapy experts to:

• Streamline CNS drug delivery devices for improved brain biodistribution
• Discover novel vectors for CNS specificity & tropism
• Optimize gene therapy strategy for pediatric & adult neurological disorders

To know more visit: https://ter.li/rluqrj